CD28 is superior to 4-1BB costimulation in generating CAR-NK cells for tumor immunotherapy
{{output}}
Chimeric antigen receptor (CAR)-NK therapy holds great potential for tumor treatment, but current CAR designs are primarily optimized for T cells, raising concerns about their suitability for NK cells. This study compared two dominant CAR designs used in T cel... ...
